Correction: iSpecimen Inc. Announces Closing of $4 Million Underwritten Offering
iSpecimen (Nasdaq: ISPC) has successfully closed its previously announced underwritten public offering, raising approximately $4 million through the sale of 5,714,283 shares of common stock at $0.70 per share. The biospecimen marketplace company plans to allocate $1.5 million for marketing services through IR Agency LLC and $1 million for an initial milestone payment to Sales Stack Solutions Corp., with the remainder designated for working capital.
WestPark Capital, Inc. served as the Sole Book-Runner for this firm commitment offering, which was conducted under an effective S-1 registration statement. This press release corrects an earlier version that incorrectly listed KCSA Strategic Communications as iSpecimen's investor relations contact.
iSpecimen (Nasdaq: ISPC) ha completato con successo la sua offerta pubblica sottoscritta precedentemente annunciata, raccogliendo circa 4 milioni di dollari attraverso la vendita di 5.714.283 azioni ordinarie al prezzo di 0,70 dollari per azione. L'azienda specializzata nel mercato dei biospecimen prevede di destinare 1,5 milioni di dollari ai servizi di marketing tramite IR Agency LLC e 1 milione di dollari come pagamento iniziale legato a un traguardo a Sales Stack Solutions Corp., mentre il resto sar脿 utilizzato come capitale operativo.
WestPark Capital, Inc. ha agito come unico book-runner per questa offerta a impegno fermo, condotta sotto un'efficace dichiarazione di registrazione S-1. Questo comunicato stampa corregge una versione precedente che indicava erroneamente KCSA Strategic Communications come contatto per le relazioni con gli investitori di iSpecimen.
iSpecimen (Nasdaq: ISPC) ha cerrado con 茅xito su oferta p煤blica suscrita anteriormente anunciada, recaudando aproximadamente 4 millones de d贸lares mediante la venta de 5.714.283 acciones ordinarias a 0,70 d贸lares por acci贸n. La empresa del mercado de biospec铆menes planea destinar 1,5 millones de d贸lares para servicios de marketing a trav茅s de IR Agency LLC y 1 mill贸n de d贸lares para un pago inicial por hitos a Sales Stack Solutions Corp., destinando el resto para capital de trabajo.
WestPark Capital, Inc. actu贸 como 煤nico book-runner para esta oferta con compromiso firme, realizada bajo una declaraci贸n de registro S-1 efectiva. Este comunicado corrige una versi贸n anterior que listaba incorrectamente a KCSA Strategic Communications como contacto de relaciones con inversionistas de iSpecimen.
iSpecimen (雮橃姢雼�: ISPC)電� 鞚挫爠鞐� 氚滍憸頃� 瓿惦 觳暯鞚� 靹标车鞝侅溂搿� 毵堦皭頃橃棳 欤茧嫻 0.70雼煬鞐� 5,714,283欤�鞚� 氤错喌欤茧ゼ 韺愲Г頃� 鞎� 400毵� 雼煬毳� 臁半嫭頄堨姷雼堧嫟. 靸濍響滊掣 鞁滌灔 須岇偓鞚� iSpecimen鞚� IR Agency LLC毳� 韱淀暅 毵堨紑韺� 靹滊箘鞀れ棎 150毵� 雼煬, Sales Stack Solutions Corp.鞐� 雽�頃� 齑堦赴 毵堨澕鞀ろ啢 歆�旮夑笀鞙茧 100毵� 雼煬毳� 氚办爼頃� 瓿勴殟鞚措┌, 雮橂ǜ歆�電� 鞖挫爠鞛愲掣鞙茧 靷毄頃� 鞓堨爼鞛呺媹雼�.
WestPark Capital, Inc.電� 鞚� 頇曥爼 鞚胳垬 瓿惦鞚� 雼弲 攵侂煬雱堧 頇滊彊頄堨溂氅�, 鞚措姅 鞙犿毃頃� S-1 霌彪 靹滊鞐� 霐半澕 歆勴枆霅橃棃鞀惦媹雼�. 鞚� 氤措弰鞛愲電� 鞚挫爠鞐� iSpecimen鞚� 韴瀽鞛� 甏�瓿� 鞐半澖觳橂ゼ KCSA Strategic Communications搿� 鞛橂 旮办灛頃� 雮挫毄鞚� 鞝曥爼頃╇媹雼�.
iSpecimen (Nasdaq : ISPC) a cl么tur茅 avec succ猫s son offre publique souscrite pr茅c茅demment annonc茅e, levant environ 4 millions de dollars gr芒ce 脿 la vente de 5 714 283 actions ordinaires au prix de 0,70 dollar par action. La soci茅t茅 sp茅cialis茅e dans le march茅 des biosp茅cimens pr茅voit d鈥檃llouer 1,5 million de dollars aux services marketing via IR Agency LLC et 1 million de dollars 脿 un paiement initial li茅 脿 un jalon 脿 Sales Stack Solutions Corp., le reste 茅tant destin茅 au fonds de roulement.
WestPark Capital, Inc. a agi en tant que seul chef de file pour cette offre ferme, r茅alis茅e sous une d茅claration d鈥檈nregistrement S-1 en vigueur. Ce communiqu茅 corrige une version ant茅rieure qui indiquait 脿 tort KCSA Strategic Communications comme contact des relations investisseurs d鈥檌Specimen.
iSpecimen (Nasdaq: ISPC) hat seine zuvor angek眉ndigte 枚ffentlich unterzeichnete Emission erfolgreich abgeschlossen und dabei rund 4 Millionen US-Dollar durch den Verkauf von 5.714.283 Stammaktien zu je 0,70 US-Dollar pro Aktie eingenommen. Das Unternehmen im Bereich Biospezimen-Marktpl盲tze plant, 1,5 Millionen US-Dollar f眉r Marketingdienstleistungen 眉ber IR Agency LLC und 1 Million US-Dollar als anf盲ngliche Meilensteinzahlung an Sales Stack Solutions Corp. zu verwenden, der Rest ist f眉r das Betriebskapital vorgesehen.
WestPark Capital, Inc. fungierte als alleiniger Book-Runner f眉r dieses verbindliche Angebot, das unter einer wirksamen S-1-Registrierungserkl盲rung durchgef眉hrt wurde. Diese Pressemitteilung korrigiert eine fr眉here Version, die f盲lschlicherweise KCSA Strategic Communications als Investor-Relations-Kontakt von iSpecimen genannt hatte.
- Secured $4 million in new funding through public offering
- Clear allocation plan for funds including marketing and strategic partnerships
- Successfully completed firm commitment offering with established underwriter
- Significant dilution through issuance of 5,714,283 new shares
- Low offering price of $0.70 per share indicates challenging market conditions
WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- This press release corrects a version issued on July 25, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen鈥檚 investor relations contact. KCSA is not currently affiliated with iSpecimen Inc. and was mistakenly included in the prior release. The corrected release is below in its entirety.
iSpecimen Inc. (Nasdaq: ISPC) (鈥渋Specimen鈥� or the 鈥淐ompany鈥�), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced on July 25, 2025 the closing of its previously announced underwritten public offering of 5,714,283 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of
The Company intends to use the net proceeds from the Offering to pay
The Offering was conducted on a firm commitment basis. WestPark Capital, Inc. acted as the Sole Book-Runner in connection with the Offering.
The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-286958), which was declared effective by the Securities and Exchange Commission (the 鈥淪EC鈥�) on July 23, 2025. The Offering is being made only by means of a written prospectus that forms a part of the registration statement. A final prospectus relating to the Offering has been filed with the SEC. Copies of the final prospectus relating to the Offering may be obtained from WestPark Capital, Inc., 1800 Century Park East, Suite 220, Los Angeles, CA 90077, tel: 310-203-2919,听e-mail:听听and are available on the SEC鈥檚 website.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit听.听
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 鈥渇orward-looking statements.鈥� These statements include, but are not limited to, statements concerning the development of our company. The words 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥減lan,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渟hould,鈥� 鈥渢arget,鈥� 鈥渨ill,鈥� 鈥渨ould鈥� and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The reader is cautioned not to rely on such forward-looking statements. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including the uncertainty regarding future commercial success; risks and uncertainties associated with market conditions and the Company鈥檚 ability to satisfy the closing conditions related to the Offering. These and other factors may cause our actual results to differ materially from any forward-looking statements. Forward-looking statements are only predictions and actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the 鈥淩isk Factors鈥� section of the Company鈥檚 Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 14, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iSpecimen specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
听
FAQ
What is the size and price of iSpecimen's (ISPC) July 2025 public offering?
How will iSpecimen (ISPC) use the proceeds from its 2025 offering?
Who was the underwriter for iSpecimen's (ISPC) July 2025 offering?
What does iSpecimen (ISPC) do as a company?
What was the correction made to iSpecimen's (ISPC) July 2025 press release?
